NEW YORK, Jan. 11, 2018 (GLOBE NEWSWIRE) -- NetworkNewsWire announces that Crystal Equity Research has published an initial
report on PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H). The report in its entirety can be viewed at the following
link: http://nnw.fm/aO8gG.
PreveCeutical is an early-stage life sciences company focused on utilizing organic and nature-identical compounds. The company
has brought one product to market and has five additional research projects currently in its development program. Its initial
product is CELLB9, a novel therapy based on blue scorpion venom. This oral solution is available for use without a prescription and
has been found to be instrumental in treating inflammation and has also been used to treat bacterial infections, pain, tumors and
more. Sales of CELLB9 represent PreveCeutical’s current revenue stream.
PreveCeutical is also pursuing additional applications for blue scorpion venom peptides, including treating low-impact brain
trauma or concussion. The Company recently signed a distribution agreement with Sports1 Marketing to address the sports medicine
market.
Highlights of the Crystal Equity Research report include discussing PreveCeutical’s recapitalization to fund its ambitious
development program. Following a reverse merger with a public shell corporation, the Company raised CA$5.3 million (US$4.3 million)
in new capital through two private placements in July 2017 and January 2018. It is believed that the Company’s current cash
resources should provide sufficient support to enable PreveCeutical to reach new commercial markets with CELLB9 and to also reach
the next milestone with its Sol-Gel drug delivery system, which is a nose-to-brain process potentially effective in reducing side
effects and increasing patient compliance for a variety of therapies. Sol-Gel is a top priority in the Company’s development
program, with cannabinoids being the first compounds under testing.
A wide-ranging development program is underway to expand PreveCeutical’s product line, with scientific efforts for each program
being undertaken at the University of Queensland in Australia and headed by PreveCeutical Chief Research Officer Harry Parekh. The
Company has a development and licensing agreement in place with UniQuest Pty. Ltd., which is the University of Queensland’s
commercial arm. This agreement ensures PreveCeutical has licensure rights to all intellectual innovations created through joint
research projects.
Other promising projects in PreveCeutical’s pipeline include:
- Smart RNA Dual Gene Therapy for treating obesity and early-stage diabetes
- Peptide and protein identification in Caribbean blue scorpion venom for purposes of engineering “nature identical”
compounds
- Non-addictive analgesics based on a new peptide library utilizing the University of Queensland’s proprietary “disulfide
linker” technology
Crystal Equity Research provided the following outlook: “Our bullish view on PreveCeutical Medical is influenced by the
Company’s plans to bring novel therapeutic compounds to the market at a time when the preventative health care market is entering a
period of rapid growth. Management has demonstrated the ability to garner investor support and raise capital at a critical time in
its development agenda, a recognized key to success for any health sciences company. Management has also been successful in
securing research and development talent through a strategic relationship with a respected and successful academic
institution.”
About PreveCeutical
PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and
nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and
development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel
platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of
various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and
oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical
sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals
extracted from a novel peptide obtained from Caribbean Blue Scorpion venom.
For more information about the company, visit www.PreveCeutical.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers,
(2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release
services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a
multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is
uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers,
journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across
the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility,
recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever
published or re-published: http://NNW.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof.
In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking statements.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
